Literature DB >> 21121903

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome.

Silvia Rasi1, Valeria Spina, Alessio Bruscaggin, Tiziana Vaisitti, Claudio Tripodo, Francesco Forconi, Lorenzo De Paoli, Marco Fangazio, Elisa Sozzi, Emanuele Cencini, Luca Laurenti, Roberto Marasca, Carlo Visco, Zijun Y Xu-Monette, Valter Gattei, Ken H Young, Fabio Malavasi, Silvia Deaglio, Gianluca Gaidano, Davide Rossi.   

Abstract

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047). The enrichment of LRP4 TT genotype in RS was confirmed in an independent series (n = 44) used for validation purposes. The LRP4 protein was expressed in CLL (n =66). Bioinformatic analysis scored LRP4 rs2306029 as a variant with possible deleterious and damaging variant of LRP4. LRP4 genotyping may help the recognition of patients with increased risk of RS at the time of CLL diagnosis.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121903     DOI: 10.1111/j.1365-2141.2010.08482.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  How we treat Richter syndrome.

Authors:  Sameer A Parikh; Neil E Kay; Tait D Shanafelt
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

Review 2.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

3.  LRP4 is critical for neuromuscular junction maintenance.

Authors:  Arnab Barik; Yisheng Lu; Anupama Sathyamurthy; Andrew Bowman; Chengyong Shen; Lei Li; Wen-cheng Xiong; Lin Mei
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

4.  LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.

Authors:  Bisei Ohkawara; Macarena Cabrera-Serrano; Tomohiko Nakata; Margherita Milone; Nobuyuki Asai; Kenyu Ito; Mikako Ito; Akio Masuda; Yasutomo Ito; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2013-11-13       Impact factor: 6.150

Review 5.  Risk factors for Richter syndrome in chronic lymphocytic leukemia.

Authors:  Sameer A Parikh; Tait D Shanafelt
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

6.  Richter Syndrome in Chronic Lymphocytic Leukemia.

Authors:  Candida Vitale; Alessandra Ferrajoli
Journal:  Curr Hematol Malig Rep       Date:  2016-02       Impact factor: 3.952

7.  Single-Nucleotide Polymorphisms Within MicroRNAs Sequences and Their 3' UTR Target Sites May Regulate Gene Expression in Gastrointestinal Tract Cancers.

Authors:  Zahra Saadatian; Andrea Masotti; Ziba Nariman Saleh Fam; Behnam Alipoor; Milad Bastami; Hamid Ghaedi
Journal:  Iran Red Crescent Med J       Date:  2014-07-05       Impact factor: 0.611

Review 8.  The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies.

Authors:  Francesca Arruga; Tiziana Vaisitti; Silvia Deaglio
Journal:  Front Oncol       Date:  2018-11-26       Impact factor: 6.244

9.  [Clinical value of PET/CT in the diagnosis of Richter syndrome].

Authors:  X Q Zheng; H Y Zhu; C Y Ding; L Wang; L Fan; W Xu; J Y Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

10.  [The relationship between NOTCH1 mutation and the Richter transformation in chronic lymphocytic leukemia].

Authors:  X L Chen; S F Wang; Z S Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.